loading
Lucid Diagnostics Inc stock is traded at $1.00, with a volume of 292.17K. It is up +0.16% in the last 24 hours and up +11.31% over the past month. Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
See More
Previous Close:
$0.9984
Open:
$1
24h Volume:
292.17K
Relative Volume:
0.92
Market Cap:
$53.84M
Revenue:
$2.43M
Net Income/Loss:
$-52.67M
P/E Ratio:
-0.6849
EPS:
-1.46
Net Cash Flow:
$-33.04M
1W Performance:
+0.00%
1M Performance:
+11.31%
6M Performance:
+9.18%
1Y Performance:
-27.01%
1-Day Range:
Value
$0.9544
$1.005
1-Week Range:
Value
$0.9499
$1.02
52-Week Range:
Value
$0.6301
$1.58

Lucid Diagnostics Inc Stock (LUCD) Company Profile

Name
Name
Lucid Diagnostics Inc
Name
Phone
212 949 4319
Name
Address
360 MADISON AVENUE, NEW YORK
Name
Employee
70
Name
Twitter
Name
Next Earnings Date
2024-11-13
Name
Latest SEC Filings
Name
LUCD's Discussions on Twitter

Compare LUCD with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Medical Devices icon
LUCD
Lucid Diagnostics Inc
1.00 53.84M 2.43M -52.67M -33.04M -1.46
Medical Devices icon
ABT
Abbott Laboratories
118.95 208.18B 41.22B 5.77B 6.49B 2.94
Medical Devices icon
SYK
Stryker Corp
388.14 148.70B 21.97B 3.59B 3.21B 6.74
Medical Devices icon
BSX
Boston Scientific Corp
90.75 133.32B 15.91B 1.79B 1.89B 0.82
Medical Devices icon
MDT
Medtronic Plc
86.27 111.27B 33.00B 4.29B 5.50B 2.71
Medical Devices icon
EW
Edwards Lifesciences Corp
72.07 42.66B 6.60B 4.16B 490.10M 2.34

Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-27-21 Initiated Ascendiant Capital Markets Buy
Nov-08-21 Initiated BTIG Research Buy
Nov-08-21 Initiated Cantor Fitzgerald Overweight
Nov-08-21 Initiated Needham Buy

Lucid Diagnostics Inc Stock (LUCD) Latest News

pulisher
Nov 27, 2024

Head-To-Head Review: Lucid Diagnostics (NASDAQ:LUCD) & DIH Holding US (NASDAQ:DHAI) - Defense World

Nov 27, 2024
pulisher
Nov 23, 2024

Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Vi - GuruFocus.com

Nov 23, 2024
pulisher
Nov 21, 2024

Lucid Diagnostics Provides Business Update and Third Quarter 202 - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

Lucid Diagnostics' SWOT analysis: stock outlook amid reimbursement progress - Investing.com

Nov 21, 2024
pulisher
Nov 20, 2024

Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test - Morningstar

Nov 20, 2024
pulisher
Nov 20, 2024

Lucid Diagnostics Announces Agreement for Sale of Senior Secured Convertible Notes - Defense World

Nov 20, 2024
pulisher
Nov 19, 2024

Lucid Diagnostics Inc. announced that it expects to receive $21.75 million in funding - Marketscreener.com

Nov 19, 2024
pulisher
Nov 18, 2024

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, D - GuruFocus.com

Nov 18, 2024
pulisher
Nov 18, 2024

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - Morningstar

Nov 18, 2024
pulisher
Nov 15, 2024

LUCDLucid Diagnostics Inc. Latest Stock News & Market Updates - StockTitan

Nov 15, 2024
pulisher
Nov 15, 2024

Cantor Fitzgerald cuts Lucid Diagnostics stock target, overweight on challenges - Investing.com India

Nov 15, 2024
pulisher
Nov 15, 2024

Lucid Diagnostics (NASDAQ:LUCD) Price Target Lowered to $2.00 at Cantor Fitzgerald - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

PAVmed Inc. (PAVM) Quarterly 10-Q Report - Quartzy

Nov 15, 2024
pulisher
Nov 15, 2024

Lucid Diagnostics (NASDAQ:LUCD) Provides Business Update and Financial Results - Defense World

Nov 15, 2024
pulisher
Nov 14, 2024

Lucid Diagnostics' (LUCD) Buy Rating Reiterated at Canaccord Genuity Group - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Needham & Company LLC Reaffirms "Buy" Rating for Lucid Diagnostics (NASDAQ:LUCD) - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

PAVmed Inc Reports Q3 2024 Earnings: Revenue at $996,000, Non-GA - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Lucid Diagnostics Inc. (NASDAQ:LUCD) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 14, 2024
pulisher
Nov 14, 2024

PAVmed Provides Business Update and Third Quarter 2024 Financial Results - Kilgore News Herald

Nov 14, 2024
pulisher
Nov 14, 2024

Earnings call: Lucid Diagnostics reports revenue growth and strategic expansion - Investing.com UK

Nov 14, 2024
pulisher
Nov 14, 2024

Lucid Diagnostics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 14, 2024
pulisher
Nov 14, 2024

Lucid Diagnostics Inc (LUCD) Q3 2024 Earnings Call Highlights: Record Revenue Growth Amid ... By GuruFocus - Investing.com Canada

Nov 14, 2024
pulisher
Nov 13, 2024

Lucid Diagnostics Reports Q3 Revenue Growth and Strategic Expansion - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

PAVMPAVmed Inc. Latest Stock News & Market Updates - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

Needham maintains Buy rating on Lucid Diagnostics shares - Investing.com

Nov 13, 2024
pulisher
Nov 13, 2024

Needham maintains Buy rating on Lucid Diagnostics shares By Investing.com - Investing.com UK

Nov 13, 2024
pulisher
Nov 13, 2024

Lucid Diagnostics Reports Revenue Growth and Secures Funding - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results - PR Newswire

Nov 13, 2024
pulisher
Nov 12, 2024

Lucid Diagnostics Announces Convertible Notes Exchange Initiative - TipRanks

Nov 12, 2024
pulisher
Nov 09, 2024

Lucid Diagnostics (LUCD) Scheduled to Post Earnings on Wednesday - MarketBeat

Nov 09, 2024
pulisher
Nov 07, 2024

Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication - BioSpace

Nov 07, 2024
pulisher
Nov 07, 2024

Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication – Company AnnouncementFT.com - Financial Times

Nov 07, 2024
pulisher
Nov 07, 2024

Finansavisen - Finansavisen

Nov 07, 2024
pulisher
Nov 05, 2024

Lucid Diagnostics expands direct contracting for cancer testing - Investing.com

Nov 05, 2024
pulisher
Nov 05, 2024

Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers - PR Newswire

Nov 05, 2024
pulisher
Nov 04, 2024

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024 - GuruFocus.com

Nov 04, 2024
pulisher
Oct 31, 2024

PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024 - Kilgore News Herald

Oct 31, 2024
pulisher
Oct 30, 2024

Lucid Diagnostics (NASDAQ:LUCD) Trading 1.5% HigherShould You Buy? - MarketBeat

Oct 30, 2024
pulisher
Oct 30, 2024

Lucid Diagnostics (NASDAQ:LUCD) Trading 1.5% Higher – Here’s What Happened - Defense World

Oct 30, 2024
pulisher
Oct 28, 2024

An unusual mascot and a former Cincinnati Bengal fight esophageal cancer - MM+M Online

Oct 28, 2024
pulisher
Oct 23, 2024

Lucid Diagnostics to Participate in Upcoming Investor Conferences - GuruFocus.com

Oct 23, 2024
pulisher
Oct 19, 2024

Lucid Diagnostics gets notice of allowance for patent underlying its esoguard esophageal DNA test - MSN

Oct 19, 2024
pulisher
Oct 16, 2024

Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test - BioSpace

Oct 16, 2024
pulisher
Oct 15, 2024

Lucid Diagnostics secures US patent for esophageal cancer test - Investing.com

Oct 15, 2024
pulisher
Oct 14, 2024

Lucid Diagnostics stock maintains Buy rating from BTIG - Investing.com India

Oct 14, 2024
pulisher
Oct 14, 2024

Lucid Diagnostics stock maintains Buy rating from BTIG By Investing.com - Investing.com South Africa

Oct 14, 2024
pulisher
Oct 11, 2024

Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL Players - Aktiellt

Oct 11, 2024
pulisher
Oct 10, 2024

PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care - StockTitan

Oct 10, 2024
pulisher
Oct 09, 2024

October's 4 Best Penny Stocks: High-Risk, High-Reward Picks - Benzinga

Oct 09, 2024
pulisher
Oct 09, 2024

Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit - PR Newswire

Oct 09, 2024
pulisher
Oct 08, 2024

Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024 - StreetInsider.com

Oct 08, 2024

Lucid Diagnostics Inc Stock (LUCD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
medical_devices STE
$217.47
price up icon 0.65%
medical_devices ZBH
$112.02
price up icon 1.25%
medical_devices PHG
$27.15
price up icon 0.89%
$78.10
price up icon 0.21%
$83.00
price up icon 0.59%
medical_devices EW
$72.07
price up icon 0.73%
Cap:     |  Volume (24h):